Pancreatic mucinous-cystic neoplasm

Summary

Pancreatic mucinous-cystic neoplasm (MONDO:0044879) is a cancer and 8 clinical trials. Top therapeutic interventions include tamoxifen. A subtype of mucinous neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pancreatic mucinous-cystic neoplasm
Mondo ID	MONDO:0044879
NCIT	C41247
UMLS	C1518872
MedGen	274120
Is cancer (heuristic)	yes

Also known as: mucinous cystic neoplasm · Pancreatic mucinous cystic neoplasm · Pancreatic mucinous-cystic neoplasm

Data availability: 1 cell line.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › glandular cell neoplasm › mucinous neoplasm › pancreatic mucinous-cystic neoplasm

Related subtypes (4): mucinous adenofibroma, fallopian tube mucinous tumor, mucinous cystadenoma, mucin-producing carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE1	2
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07262957	PHASE4	RECRUITING	Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
NCT03188991	PHASE2	COMPLETED	Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
NCT06320990	PHASE1	RECRUITING	Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection
NCT02213419	PHASE1	UNKNOWN	Endoscopic Ultrasonography-guided Double Ethanol Lavage for Pancreatic Cysts: a Prospective Cohort Study
NCT06638866	Not specified	RECRUITING	AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
NCT07117045	Not specified	RECRUITING	Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
NCT02110498	Not specified	COMPLETED	Early Detection of Pancreatic Cystic Neoplasms
NCT02494388	Not specified	TERMINATED	Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TAMOXIFEN	4	1